(i)

On August 1, 2025, the Company granted 65,936 performance base restricted share units to the CEO, CFO, COO and VP Research. The performance milestones relate to the achievement of certain objectives as set out by the board of directors. On the same day, the Company granted 37,700 stock options to certain employees and scientific advisory board members. The stock options have an exercise price of $12.50, vest quarterly over 2 years, and expire 5 years from the grant date.

(ii)

On September 25, 2025, the Company granted 100,000 PSU’s to the chairman, linked to the milestones of the CEO and CMO and on the same day, the Company granted 40,000 RSU’s to the non-executive directors. The RSU’s best in three years from the date of issuance.

(iii)

On August 25, 2025, the Company was awarded a non-dilutive research grant of approximately US$2.05 million from the U.S. National Cancer Institute (NCI) to advance the clinical development of Bria-PROS+™, the Company’s personalized off-the-shelf immunotherapy for prostate cancer. The grant will fund the completion of manufacturing of Bria-PROS+™ clinical supply and support the upcoming Phase 1/2a clinical trial in metastatic prostate cancer.